Granite FO LLC’s Royalty Pharma RPRX Stock Holding History

Granite FO LLC’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,401	Closed	-$106K	–	239
2022 Q4	$106K	Buy	+2,401	New	+$100K	0.08%	72

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Granite FO LLC's RPRX Position: Q1 2023 in Review

Granite FO LLC sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 2,401 shares — an estimated $106K sold.

Granite FO LLC first reported a position in RPRX in Q4 2022 and held it in 1 quarter. The position peaked at $106K in Q4 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

Granite FO LLC reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
Granite FO LLC sold 2,401 Royalty Pharma shares in Q1 2023, an estimated $106K.
Granite FO LLC first reported a position in Royalty Pharma in Q4 2022 and held it in 1 quarter.
Granite FO LLC's Royalty Pharma position peaked at $106K in Q4 2022.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Granite FO LLC's 13F filing for Q1 2023, filed 5 Sep 2024.